We use cookies to customise content for your subscription and for analytics.
If you continue to browse Lexology, we will assume that you are happy to receive all our cookies. For further information please read our Cookie Policy.

Search results

Order by: most recent most popular relevance



Results: 1-10 of 3,666

IP in depth: patentable biotechnology a comparative analysis of key markets
  • Fisher Adams Kelly Callinans
  • Australia, European Union, New Zealand, USA
  • March 31 2015

There is extraordinary complexity and optimization underlying even comparatively 'simple' organisms. These powerful biological products and processes


Some customs and trade aspects in the life sciences industry
  • Bird & Bird
  • European Union
  • May 22 2015

Economic operators in the life sciences industry can face numerous issues when bringing and trading life sciences products in the European Union


EU political update: 7 11 September 2015
  • Clifford Chance LLP
  • European Union
  • September 7 2015

On 4 September 2015, the European Commission made public the results of the 'VAT Gap' study, which is funded by the Commission as part of its work to


Mental capacity law newsletter September 2015: issue 58 - compendium
  • 39 Essex Chambers
  • European Union, United Kingdom
  • September 7 2015

The fall out from Re X continues. We anticipate judgment being handed down very shortly by Charles J, the Vice-President of the Court of Protection


WP 29 defines the scope of health data collected by mobile apps and devices
  • Stibbe
  • European Union
  • April 30 2015

In light of the Internet of Things, mobile apps that are installed in smartphones, other portable electronic devices, and smartwear devices collect


EMA publishes a draft Q&A document for consultation on the environmental risk assessment guidelines
  • Hogan Lovells
  • European Union
  • April 13 2015

On 26 March 2015, the European Medicines Agency (“EMA”) published a draft Questions and Answers Document (“Q&A Document“) for consultation concerning


Private health insurer recovers surgical costs of replacing defective medical products
  • William Fry
  • European Union
  • April 13 2015

The European Court of Justice has held that a manufacturer of pacemakers and implantable cardioverter defibrillators must reimburse a private health


EMA confirms that access to clinical study reports for preparation of health technology dossiers will be permitted within the new EMA Disclosure Policy
  • Hogan Lovells
  • European Union
  • April 13 2015

According to the minutes of a meeting between the European Medicines Agency ("EMA") and the European Network for Health Technology Assessment


EMA permits the use of a comparator product authorised outside the EEA in clinical studies for biosimilars
  • Hogan Lovells
  • European Union
  • April 13 2015

The European Medicines Agency's ("EMA") revised overarching guideline on biosimilars("Guideline"), which was published on 23 October 2014, will come


The Council adopts its position on revised medical devices package
  • Hogan Lovells
  • European Union
  • June 23 2015

On 19 June 2015, the Council of the European Union ("Council") came to a common position, during a meeting of the Employment, Social Policy, Health